Hypothesis\nSleep does not merely permit autophagy; it triggers a two‑step molecular switch that couples the circadian clock to lysosomal readiness. During wakefulness, inflammatory signaling maintains BCL‑2 phosphorylated at Ser70, which locks Beclin‑1 in an inactive complex. Sleep onset drives a rapid dephosphorylation of BCL‑2 Ser70 via protein phosphatase 2A (PP2A), releasing Beclin‑1 to initiate autophagosome formation. Simultaneously, the rise in extracellular adenosine during sleep inhibits mTORC1, allowing V‑ATPase assembly on lysosomes and acidification. Only when both events coincide—BCL‑2 dephosphorylation and mTORC1 suppression—does the cell execute autophagic triage, degrading selectively damaged proteins and organelles. Aging or chronic sleep loss sustains BCL‑2 Ser70 phosphorylation and blunts adenosine accumulation, uncoupling Beclin‑1 release from lysosomal activation and yielding a pool of idle autophagosomes that cannot mature, thus explaining the observed increase in Beclin‑1 protein without flux.\n\n## Mechanistic Model\n1. Circadian input – Core clock component BMAL1 drives nightly expression of PP2A regulatory subunits, peaking in NREM sleep.\n2. Sleep‑dependent metabolite – Adenosine accumulates as neuronal firing declines, binding A1 receptors to inhibit adenylyl cyclase, lowering cAMP and reducing PKA‑mediated mTORC1 activity.\n3. BCL‑2 regulation – PP2A dephosphorylates BCL‑2 at Ser70, decreasing its affinity for Beclin‑1; phosphorylated BCL‑2 retains high affinity and blocks autophagy.\n4. Lysosomal priming – Low mTORC1 permits TFEB nuclear translocation and V‑ATPase subunit transcription, acidifying lysosomes for autophagosome‑lysosome fusion.\n5. Outcome – When both switches are ON, autophagosomes engulf ubiquitinated cargo and fuse with acidified lysosomes; when either is OFF, autophagosomes stall, leading to Beclin‑1 accumulation without degradation.\n\n## Predictions & Tests\n- In young mice, phospho‑BCL‑2 (Ser70) levels will be low during NREM sleep and high during wake; aged mice will show persistently high phospho‑BCL‑2 across the sleep‑wake cycle.\n- Pharmacological inhibition of PP2A (e.g., okadaic acid low dose) during sleep will prevent Beclin‑1 release and reduce LC3‑II flux despite normal adenosine levels.\n- Chemogenetic elevation of extracellular adenosine during wakefulness will lower mTORC1 activity but will not restore flux unless BCL‑2 is dephosphorylated (i.e., PP2A activity present).\n- Expression of a BCL‑2 S70A mutant (non‑phosphorylatable) in aged mice will rescue nightly autophagic flux and reduce amyloid‑beta accumulation, even if adenosine signaling remains impaired.\n- Simultaneous measurement of lysosomal pH (using LysoSensor) and autophagosome number (GFP‑LC3 puncta) will show that only when lysosomal pH <5.0 and BCL‑2 dephosphorylation co‑occur does GFP‑LC3 signal decrease (indicating degradation).\n\n## Potential Confounds\nChanges in vascular pulsatility or AQP4 polarity could independently affect glymphatic clearance and thus secondarily influence autophagy readouts; experiments should isolate parenchymal autophagy by using in‑vitro neuronal cultures with controlled sleep‑like conditions (serum starvation + adenosine agonists) and monitor BCL‑2 phosphorylation and lysosomal acidification.\n\nIf these predictions hold, the nightly "autopsy" is not a passive waste‑dump but a gated, two‑factor checkpoint where sleep‑dependent signaling both frees the autophagic engine and primes its lysosomal destination, offering a precise point of intervention for age‑related proteostatic decline.